Immune checkpoint inhibition in lymphoid disease
نویسندگان
چکیده
منابع مشابه
Immune checkpoint inhibition in lymphoid disease.
It has long been understood that the immune system has intrinsic anti-tumour activity in humans, and that a key mechanism of tumour progression is the ability of a tumour to escape this immune surveillance. A number of attempts have been made to harness this anti-tumour immunity in both solid tumour oncology and haematological malignancies with variable success. Examples include the use of allo...
متن کاملImmune Checkpoint Inhibition in Advanced Cancer
Following the success of single agent CTLA-4 and PD-1 inhibition, focus has shifted to the study of novel combinations of immune therapeutics with the goal of improving efficacy. A major breakthrough was seen in CheckMate 067 as dual PD1/CTLA4 blockade demonstrated robust and often durable responses. However, this efficacy came at the cost of considerable toxicity, as ≥ 50% of patients on combi...
متن کاملImmune checkpoint receptors in regulating immune reactivity in rheumatic disease
Immune checkpoint regulators are critical modulators of the immune system, allowing the initiation of a productive immune response and preventing the onset of autoimmunity. Co-inhibitory and co-stimulatory immune checkpoint receptors are required for full T-cell activation and effector functions such as the production of cytokines. In autoimmune rheumatic diseases, impaired tolerance leads to t...
متن کاملSelecting patients for immune checkpoint inhibition in lung cancer.
EG Yes, several studies are underway or beginning to enroll patients that are looking at immune checkpoint inhibitors as adjuvant therapy in early-stage disease. In the international PACIFIC study, researchers are randomly assigning patients with locally advanced, unresectable NSCLC after chemoradiotherapy to receive either the experimental programmed cell death ligand 1 (PD-L1) inhibitor MEDI4...
متن کاملImmune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
The co-inhibitory receptor programmed cell death (PD)-1, expressed by immune effector cells, is credited with a protective role for normal tissue during immune responses, by limiting the extent of effector activation. Its presently known ligands, programmed death ligands (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2015
ISSN: 0007-1048
DOI: 10.1111/bjh.13397